Abstract: The invention discloses a purified albumin solution of human origin with low prekallicrein activator (PKA) activity and stability over time characterized in that it has an antithrombin content equal to or greater than 0.03 mg/g of albumin, and a process for production thereof by the partial extraction of the antithrombin during fractionation of the human plasma.

Abstract: Composition of biocompatible microparticles of alginic acid for the controlled release of active ingredients by intravenous administration. The invention relates to a biocompatible composition which comprises microparticles of alginic acid or its salts and an active ingredient. More particularly, the invention relates to microparticles for the encapsulation of an active ingredient to be administered intravenously to a patient who needs it. These microparticles are of a combination of size sufficient to increase the half-life or survival of the active ingredient in blood, with a low uptake in the liver and a fast cell clearance when administered intravenously.

Abstract: The present invention relates to the use of therapeutic human albumin for the preparation of a drug for the treatment of patients suffering from cognitive disorders. In particular, the invention relates to methods of treating patients suffering from cognitive disorders, in which the mode of administration of the drug comprises the administration to the patient for a minimum of three successive times of a therapeutically effective amount of human therapeutic albumin by plasma exchange and/or intravenous perfusion, independently of the content of A? in the patient's blood.

Abstract: The apparatus comprises an assembly of modules functionally interrelated with one another, and controlled by means of a central control unit in an embodiment of circular type in concentric rings of a reagent module and a rotatory carousel carrying the incubation reaction containers, with adjacent and external arrangement of a module for feeding the disposable reaction containers by means of detachable racks and a scanning device likewise concentric with the carousel, combining with a unit for feeding by pushing the reaction containers from the racks towards the grooves of the incubation carousel, and of two displacement arm devices.

Abstract: The process is characterised by the preparation of a solution of Von Willebrand Factor or a complex of Factor VIII/Von Willebrand Factor which contains VWF and a concentration of up to 12 IU VWF:RCo/ml and a Von Willebrand Factor/Factor VIII ratio of 0.4 or more; and then proceeding with nanofiltration of the solution prepared in a) through a filter having a pore size of less than 35 nanometres.

Abstract: The therapeutic preparation of FVIIa having a purity of at least 1000 IU/mg of protein is characterized in that said preparation is free of proteins of non-human origin. In the method for obtaining FVII, purification starts from FrII+III, FrIII or equivalent of Cohn fractioning and comprises precipitation with PEG, chromatography and its subsequent activation.

Abstract: Apparatus for measuring the optical absorbency of samples of liquids, method and reaction container for its implementation. The apparatus comprises a receiving body for receiving the reaction containers carrying the samples to be analyzed, with means for causing each of the reaction containers to be passed through by a luminous signal of controlled wavelength, having means for conducting it to a scanning head where the luminous signals are picked up by a single CCD sensor, constituting a digital processing system for evaluating the absorbency of the corresponding sample.

Abstract: A process for removing viruses in fibrinogen solutions and fibrinogen obtained thereof wherein the process starts with an adjusted purified fibrinogen solution, the adjusted purified solution is frozen and then thawed at a temperature between 5 and 20° C., the undissolved materials associated with the fibrinogen are subsequently separated, the temperature is adjusted and the resultant solution is finally subjected to nanofiltration using filters having a pore size smaller than 35 nm.

Abstract: The invention discloses a purified albumin solution of human origin with low prekallicrein activator (PKA) activity and stability over time characterised in that it has an antithrombin content equal to or greater than 0.03 mg/g of albumin, and a process for production thereof by the partial extraction of the antithrombin during fractionation of the human plasma.

Abstract: The invention is based on feeding the closed bodies to be evaluated to a station for the application of high voltage for the formation of the arc across the inner space of the body and capturing the arc formed by means of a CCD camera which will compare, adjustably, the luminous intensity of the arc created within the body subjected to checking with a threshold value determining whether the luminous intensity is above or below the threshold, which will be the rejection threshold, rejecting the bodies which do not comply with the predetermined threshold value, separating them from the whole of the accepted bodies.

Abstract: The invention is based on the use of alpha-1 antitrypsin for the preparation of medicaments for the treatment of fibromyalgia, comprising the preparation of therapeutic concentrates of alpha-1 antitrypsin, in any form of administration tolerated by humans, the alpha-1 antitrypsin being obtained by purification of human plasma or being produced by recombinant or transgenic technology, with doses equal to or greater than 6 mg of alpha-1 antitrypsin per kg of body weight for a variable period of time.

Abstract: A main metering body has a coupling for a manual pump for filling the hardenable mass for vertebroplastia, permitting its independent filling and its subsequent introduction into the metering body, which is equipped with an end coupling for a high pressure flexible tubular member that can be coupled to the needle for introducing the hardenable mass, capable of being inserted on a long stylet for the initial puncture operation and a short stylet for the second and final puncture to the site where vertebroplastia is to be carried out.

Abstract: The apparatus comprises a transportable unit with a support base which is provided with wheels and which carries a source for the supply of CO2 under regulated pressure, having a support foot provided, at the top, with an articulated arm carrying a programming and control screen and means for receiving an exchangeable metering device capable of receiving the CO2 by way of ducts coming from the CO2 source and of metering it to an outlet for a catheter for administration to the patient, having motorised means capable of actuating the intake of CO2 into the metering device and of actuating the valves thereof in order to control the administration of the gas.

Abstract: The apparatus has two main regions of members the operation of which is controlled separately, the first region, to which the user has interactive access, permitting loading of the samples, controls, calibrators, diluents and other equipment for performing the sampling and dilutions and receiving the plate on which the tests are performed, and the second region, to which the user has occasional access, comprising stations dedicated to the rest of the process including incubation, washing, reading, and others, the second region being able to hold several plates at different stages of the process, the apparatus having means for automated movement along three coordinate axes X, Y, Z in order to transport the reagents and the plates in order to complete the process, enabling several tests to be performed at the same time on a set of samples in one or several plates, and enabling new series of tasks with the same or different sets of tests and with the same or different sets of samples to be started when the previ

Abstract: A universal apparatus for clinical analysis is provided comprising a base-board having three main levels. The first level holds a terminal for containers of reagents and samples and includes a device for cyclically vibrating individual vials. External graphic marks on vials and bottles and the internal characteristics of the same, such as the level of contents can be read. The second level of the base-board includes a thermostatic block which is provided with a number of grooves which can receive either disposable strips of small analytical containers or analytical cards. An agglutination reader is also provided. The third level carries a centrifuge which receives either strips or cards from a collection head having a clamp for collecting, conveying and placing in position the strips and cards; the head also including a pipetting needle.

Abstract: An efficient industrial method, by incubation at extreme (alkaline) pH in a stabilized medium, of inactivating viruses in general (with or without a lipid envelope) in media containing proteins for therapeutic use, without denaturing or significant loss of biological activity.

Abstract: There is described a therapeutic human albumin having a very low capacity for the absorption of aluminium, during storage in a glass receptacle, wherein the final composition of the albumin solution adjusted to be stable and isotonic at a concentration of 5, 20 or 25% of protein in an aqueous medium, preferably, or to any other therapeutic concentration acceptable for intravenous administration, has a citrate content in the final albumin composition equal to or less than 0.5 mM (millimolar) and, preferably, less than 0.037 mM (millimolar).

Abstract: The present invention provides a device for carrying out erythrocytic reactions, wherein the device includes a molded plate having multiple individual reaction compartments, each formed by an upper and lower chamber. The upper chamber is adapted to receive liquid for the first phase of the erythrocytic reaction which consists of dispensing reagents and samples, and the lower chamber contains a separating medium and reagents for the second phase of the reaction, wherein one or more products of the first phase are contacted with the contents of the lower chamber. The upper chamber communicates with the lower chamber through a narrow gap having a controlled width, such that the meniscus formed by surface tension prevents passage of the liquid in the upper chamber to the lower chamber, wherein centrifugation triggers the passage of liquid from one chamber to another.